How much profit has ChemPartner PharmaTech Co made this year?
ChemPartner PharmaTech Co has made -907.94 M CNY this year.
ChemPartner PharmaTech Co Net Income 2024
ChemPartner PharmaTech Co Net Income
-907.94 M CNY
Ticker
300149.SZ
ISIN
CNE100000Y27
In 2024, ChemPartner PharmaTech Co's profit amounted to -907.94 M CNY, a -339.83% increase from the 378.59 M CNY profit recorded in the previous year.
The ChemPartner PharmaTech Co Net Income history
| YEAR | NET INCOME (undefined CNY) |
|---|---|
| 2023 | -907.94 |
| 2022 | 378.59 |
| 2021 | -402.25 |
| 2020 | 154.6 |
| 2019 | 138.9 |
| 2018 | 161.1 |
| 2017 | 57.8 |
| 2016 | 65 |
| 2015 | 59.5 |
| 2014 | 40.7 |
| 2013 | 39.7 |
| 2012 | 35.3 |
| 2011 | 27.5 |
| 2010 | 33.8 |
| 2009 | 29.4 |
| 2008 | 23.2 |
| 2007 | 12 |
ChemPartner PharmaTech Co Revenue, EBIT, Net Income CNE100000Y27 ·
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into ChemPartner PharmaTech Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by ChemPartner PharmaTech Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects ChemPartner PharmaTech Co’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of ChemPartner PharmaTech Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into ChemPartner PharmaTech Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing ChemPartner PharmaTech Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on ChemPartner PharmaTech Co’s growth potential.
ChemPartner PharmaTech Co Revenue, EBIT and net profit per share
| Date | ChemPartner PharmaTech Co Revenue | ChemPartner PharmaTech Co EBIT | ChemPartner PharmaTech Co Net Income |
|---|---|---|---|
| 2023 | 1.14 B undefined | -128.47 M undefined | -907.94 M undefined |
| 2022 | 1.33 B undefined | -222.27 M undefined | 378.59 M undefined |
| 2021 | 1.69 B undefined | 82.29 M undefined | -402.25 M undefined |
| 2020 | 1.48 B undefined | 277.9 M undefined | 154.6 M undefined |
| 2019 | 1.33 B undefined | 189.7 M undefined | 138.9 M undefined |
| 2018 | 996.9 M undefined | 189.8 M undefined | 161.1 M undefined |
| 2017 | 275.4 M undefined | 52.9 M undefined | 57.8 M undefined |
| 2016 | 258.6 M undefined | 68.2 M undefined | 65 M undefined |
| 2015 | 318.6 M undefined | 61.8 M undefined | 59.5 M undefined |
| 2014 | 281.2 M undefined | 41.2 M undefined | 40.7 M undefined |
| 2013 | 256.7 M undefined | 31.7 M undefined | 39.7 M undefined |
| 2012 | 238.7 M undefined | 37.1 M undefined | 35.3 M undefined |
| 2011 | 166.1 M undefined | 23.3 M undefined | 27.5 M undefined |
| 2010 | 123.8 M undefined | 36.7 M undefined | 33.8 M undefined |
| 2009 | 100.2 M undefined | 35 M undefined | 29.4 M undefined |
| 2008 | 97.1 M undefined | 28 M undefined | 23.2 M undefined |
| 2007 | 65.1 M undefined | 14.1 M undefined | 12 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2007 | 65.1 M CNY | 14.1 M CNY | 12 M CNY |
| 2008 | 97.1 M CNY | 28 M CNY | 23.2 M CNY |
| 2009 | 100.2 M CNY | 35 M CNY | 29.4 M CNY |
| 2010 | 123.8 M CNY | 36.7 M CNY | 33.8 M CNY |
| 2011 | 166.1 M CNY | 23.3 M CNY | 27.5 M CNY |
| 2012 | 238.7 M CNY | 37.1 M CNY | 35.3 M CNY |
| 2013 | 256.7 M CNY | 31.7 M CNY | 39.7 M CNY |
| 2014 | 281.2 M CNY | 41.2 M CNY | 40.7 M CNY |
| 2015 | 318.6 M CNY | 61.8 M CNY | 59.5 M CNY |
| 2016 | 258.6 M CNY | 68.2 M CNY | 65 M CNY |
| 2017 | 275.4 M CNY | 52.9 M CNY | 57.8 M CNY |
| 2018 | 996.9 M CNY | 189.8 M CNY | 161.1 M CNY |
| 2019 | 1.33 B CNY | 189.7 M CNY | 138.9 M CNY |
| 2020 | 1.48 B CNY | 277.9 M CNY | 154.6 M CNY |
| 2021 | 1.69 B CNY | 82.29 M CNY | -402.25 M CNY |
| 2022 | 1.33 B CNY | -222.27 M CNY | 378.59 M CNY |
| 2023 | 1.14 B CNY | -128.47 M CNY | -907.94 M CNY |
ChemPartner PharmaTech Co stock margins CNE100000Y27 ·
The ChemPartner PharmaTech Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of ChemPartner PharmaTech Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for ChemPartner PharmaTech Co.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the ChemPartner PharmaTech Co's sales revenue. A higher gross margin percentage indicates that the ChemPartner PharmaTech Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the ChemPartner PharmaTech Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the ChemPartner PharmaTech Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the ChemPartner PharmaTech Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the ChemPartner PharmaTech Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the ChemPartner PharmaTech Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
ChemPartner PharmaTech Co Margin History
| ChemPartner PharmaTech Co Gross margin | ChemPartner PharmaTech Co Profit margin | ChemPartner PharmaTech Co EBIT margin | ChemPartner PharmaTech Co Profit margin |
|---|---|---|---|
| 2023 | 23.47 % | -11.29 % | -79.76 % |
| 2022 | 24.8 % | -16.75 % | 28.54 % |
| 2021 | 31.5 % | 4.87 % | -23.79 % |
| 2020 | 38.15 % | 18.76 % | 10.43 % |
| 2019 | 37.83 % | 14.29 % | 10.46 % |
| 2018 | 42.8 % | 19.04 % | 16.16 % |
| 2017 | 45.61 % | 19.21 % | 20.99 % |
| 2016 | 50.5 % | 26.37 % | 25.14 % |
| 2015 | 48.9 % | 19.4 % | 18.68 % |
| 2014 | 47.94 % | 14.65 % | 14.47 % |
| 2013 | 41.6 % | 12.35 % | 15.47 % |
| 2012 | 39.42 % | 15.54 % | 14.79 % |
| 2011 | 33.35 % | 14.03 % | 16.56 % |
| 2010 | 46.28 % | 29.64 % | 27.3 % |
| 2009 | 51 % | 34.93 % | 29.34 % |
| 2008 | 45.31 % | 28.84 % | 23.89 % |
| 2007 | 43.32 % | 21.66 % | 18.43 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2007 | 43.32 % | 21.66 % | 18.43 % |
| 2008 | 45.31 % | 28.84 % | 23.89 % |
| 2009 | 51 % | 34.93 % | 29.34 % |
| 2010 | 46.28 % | 29.64 % | 27.3 % |
| 2011 | 33.35 % | 14.03 % | 16.56 % |
| 2012 | 39.42 % | 15.54 % | 14.79 % |
| 2013 | 41.6 % | 12.35 % | 15.47 % |
| 2014 | 47.94 % | 14.65 % | 14.47 % |
| 2015 | 48.9 % | 19.4 % | 18.68 % |
| 2016 | 50.5 % | 26.37 % | 25.14 % |
| 2017 | 45.61 % | 19.21 % | 20.99 % |
| 2018 | 42.8 % | 19.04 % | 16.16 % |
| 2019 | 37.83 % | 14.29 % | 10.46 % |
| 2020 | 38.15 % | 18.76 % | 10.43 % |
| 2021 | 31.5 % | 4.87 % | -23.79 % |
| 2022 | 24.8 % | -16.75 % | 28.54 % |
| 2023 | 23.47 % | -11.29 % | -79.76 % |
ChemPartner PharmaTech Co Aktienanalyse
What does ChemPartner PharmaTech Co do?
ChemPartner PharmaTech Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding ChemPartner PharmaTech Co's Profit Margins
The profit margins of ChemPartner PharmaTech Co represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of ChemPartner PharmaTech Co's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating ChemPartner PharmaTech Co's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
ChemPartner PharmaTech Co's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When ChemPartner PharmaTech Co’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about ChemPartner PharmaTech Co stock
How has the profit developed compared to last year?
The profit has increased by -339.83% compared to last year fallen
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does ChemPartner PharmaTech Co publish its earnings?
ChemPartner PharmaTech Co publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of ChemPartner PharmaTech Co?
The profits of ChemPartner PharmaTech Co are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of ChemPartner PharmaTech Co?
You can learn more about the earnings of ChemPartner PharmaTech Co by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does ChemPartner PharmaTech Co pay?
Over the past 12 months, ChemPartner PharmaTech Co paid a dividend of 0.07 CNY . This corresponds to a dividend yield of about 1.59 %. For the coming 12 months, ChemPartner PharmaTech Co is expected to pay a dividend of 0 CNY.
What is the dividend yield of ChemPartner PharmaTech Co?
The current dividend yield of ChemPartner PharmaTech Co is 1.59 %.
When does ChemPartner PharmaTech Co pay dividends?
ChemPartner PharmaTech Co pays a quarterly dividend. This is distributed in the months of June, June, July, July.
How secure is the dividend of ChemPartner PharmaTech Co?
ChemPartner PharmaTech Co paid dividends every year for the past 0 years.
What is the dividend of ChemPartner PharmaTech Co?
For the upcoming 12 months, dividends amounting to 0 CNY are expected. This corresponds to a dividend yield of 0 %.
In which sector is ChemPartner PharmaTech Co located?
ChemPartner PharmaTech Co is assigned to the 'Health' sector.
Wann musste ich die Aktien von ChemPartner PharmaTech Co kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of ChemPartner PharmaTech Co from 6/1/2021 amounting to 0.07 CNY, you needed to have the stock in your portfolio before the ex-date on 6/1/2021.
When did ChemPartner PharmaTech Co pay the last dividend?
The last dividend was paid out on 6/1/2021.
What was the dividend of ChemPartner PharmaTech Co in the year 2023?
In the year 2023, ChemPartner PharmaTech Co distributed 0.07 CNY as dividends.
In which currency does ChemPartner PharmaTech Co pay out the dividend?
The dividends of ChemPartner PharmaTech Co are distributed in CNY.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von ChemPartner PharmaTech Co
Our stock analysis for ChemPartner PharmaTech Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ChemPartner PharmaTech Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- ChemPartner PharmaTech Co Revenue
- ChemPartner PharmaTech Co Net Income
- ChemPartner PharmaTech Co P/E
- ChemPartner PharmaTech Co P/S
- ChemPartner PharmaTech Co EBIT
- ChemPartner PharmaTech Co Dividend
- ChemPartner PharmaTech Co Stocks
- ChemPartner PharmaTech Co Market capitalization
- ChemPartner PharmaTech Co Debt
- ChemPartner PharmaTech Co Liabilities
- ChemPartner PharmaTech Co Equity
- ChemPartner PharmaTech Co AAQS
- ChemPartner PharmaTech Co Employees
- ChemPartner PharmaTech Co ROE
- ChemPartner PharmaTech Co ROA
- ChemPartner PharmaTech Co ROCE